Pharmacia

Pharmacia. The company was a major multinational pharmaceutical and biotechnology firm with deep roots in Sweden. For much of the 20th century, it was a central player in the global pharmaceutical industry, known for pioneering work in areas like ophthalmology, oncology, and biotechnology. Its complex corporate history, marked by significant mergers and acquisitions, ultimately led to its absorption into the world's largest drugmaker, reshaping the competitive landscape.

History

The original company was founded in 1911 in Stockholm as a subsidiary of the Kreuger & Toll conglomerate, initially focusing on importing pharmaceuticals. A pivotal early development was its acquisition of the rights to produce Insulin in Scandinavia following the landmark discovery by Frederick Banting and Charles Best. In 1948, it introduced the first commercially prepared dextran-based blood plasma substitute, a significant innovation in World War II-era medicine. The modern entity was effectively created in 1990 through the merger of the Swedish Pharmacia AB and the American Upjohn company, forming Pharmacia & Upjohn with headquarters in London. This merger was part of a major consolidation trend within the global pharmaceutical industry during that period. Further transformational change occurred in 1995 when it merged with the Florence-based Farmitalia and the United States biotechnology firm Sugen, significantly expanding its research pipeline.

Products and innovations

The company's portfolio included several landmark therapeutic agents that achieved global recognition. In ophthalmology, it developed and marketed Healon (sodium hyaluronate), a vital product used in cataract surgery and other surgical procedures. Its oncology division was responsible for important chemotherapy drugs such as Farlutal and Farmorubicin. Perhaps its most famous and controversial product was the COX-2 inhibitor Celebrex (celecoxib), which it co-promoted with Pfizer and which became a blockbuster treatment for arthritis. In the field of biotechnology, its subsidiary Pharmacia Biotech was a leading manufacturer of equipment for protein purification and DNA sequencing, including the FPLC and Gene Assembler systems, which were foundational tools in molecular biology laboratories worldwide. The company also had a strong presence in endocrinology with drugs like Genotropin (somatropin).

Corporate structure and acquisitions

The corporate narrative was defined by aggressive expansion and strategic realignments. Following the 1990 merger that created Pharmacia & Upjohn, the company struggled with integration challenges between its Swedish and American operations. A major strategic shift occurred in 2000 when it divested its Pharmacia Biotech division to Amersham plc, which later became part of GE Healthcare. That same year, it executed a monumental merger with the Monsanto Company and its G.D. Searle & Company pharmaceutical unit, adopting the Pharmacia name for the combined entity while planning to spin off the Monsanto agricultural business. This move brought the blockbuster drug Celebrex fully into its portfolio and expanded its research base in St. Louis. The merged company established its operational headquarters in Peapack, while maintaining a significant presence in Stockholm and Kalamazoo.

Legacy and impact

The primary legacy is its role in the consolidation of the global pharmaceutical industry, culminating in its 2003 acquisition by Pfizer in a transaction valued at approximately $60 billion. This deal, one of the largest in business history at the time, gave Pfizer full control of Celebrex and bolstered its pipelines in oncology and endocrinology. Many of its former research facilities, such as those in Stockholm (now AstraZeneca R&D) and Kalamazoo, remain important centers for pharmaceutical innovation. Its biotechnology instrumentation division, through Amersham and later GE Healthcare, continued to influence proteomics and genomics research for years. The Pharmacia name itself persists on many legacy products and in the historical records of major institutions like the Karolinska Institute, reflecting its enduring impact on medical science and corporate strategy within a highly competitive global sector. Category:Pharmaceutical companies of Sweden Category:Companies established in 1911 Category:Companies disestablished in 2003